Global Corrosion Resistant Resin Market Size, Share, Development, Growth and Demand Forecast to 2022

The global corrosion resistant resin market has been segmented by type, application, end use industry and region. On the basis of type, the global market has been segmented into epoxy, polyester, polyurethane, and vinyl ester. On the basis of application, the market has been segmented into coatings, and composites; whereas, on the basis of end use industry, the market has been segmented into oil and gas, heavy industries, automotive and transportation, infrastructure, and marine.

Industries experience huge losses due to corrosion every year, which could be a direct threat to both property and people. Corrosion resistant resins help in minimalizing these losses, thereby preventing damage to structures, equipment, and machinery.

To Browse Full Report Visit Here: https://www.psmarketresearch.com/market-analysis/corrosion-resistant-resin-market

The global corrosion resistant resin market is witnessing growth, owing to increasing monetary losses due to corrosion and growth of the end-use industries. Another important factor that is likely to support the growth of this market is modernization of infrastructure. Moreover, there are other factors supporting the growth of the global market, including demand from end-use industries, particularly from oil and gas and automotive and transportation industries.

Factors such as fluctuating raw material cost are restraining the growth of the global corrosion resistant resin market. Most of the raw materials used in the production of corrosion resistant resin are petroleum products, due to which, the prices of these raw materials have been highly volatile in recent times, affecting the growth of the market.

On the basis of type, Epoxy is the most commonly used material for coatings and composites applications. Epoxy is increasingly being used due to its excellent properties such as corrosion resistance, low cost, and easy application.

Browse For Related Research Visit Here: https://www.psmarketresearch.com/industry-report/chemicals-and-materials

Based on application, composites application segment is likely to grow at a higher pace, owing to the growing demand for lightweight materials from automotive and transportation, oil and gas and heavy industries, and various other end use industries to reduce the maintenance cost.

On the basis of end use industry, the oil and gas industry uses corrosion resistant resin on a large scale. Coatings is one of the traditional and economic ways to protect assets from corrosion. Monetary losses due to corrosion could be high in industries. Therefore, corrosion resistant resin is being used in the form of coatings and composites in various end use industries, such as heavy industries, marine and oil and gas industries, among others.

By region. the global corrosion resistant resin market has been segmented into North America, Europe, Asia-Pacific, Middle East and Africa and Rest of the world.

Get More Information Visit : P&S Market Research

Programmed Death-1 and Programmed Death Ligand-1 Inhibitors Pipeline Analysis, Market Development and Demand Forecast to 2025

The global programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors market is valued at an estimated $4,926.4 million in 2016, and it is expected to grow at a CAGR of 23.4% during 2017 - 2025.

The growth of the global market is largely driven by the increased investment and funding, strong pipeline, and improved safety and efficacy. BGB-A317, a Phase I therapeutic candidate of BeiGene Ltd., gained $75 million funding to continued development of targeted oncology candidate. PD-1 and PD-L1 inhibitors are applicable to a wider range of tumor types such as advanced or metastatic non-small cell lung cancer, renal cancer, melanoma and others. These inhibitors lower the rate of severe toxicities and immune-mediated side-effects. These are also convenient to administer, and yield a good response rate of any single-agent immunotherapy. This creates huge traction in pharmaceutical industry to develop PD-1 and PD-L1 inhibitors for treatment of different types of cancer.

Explore Report with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/pd1-and-pdl1-inhibitors-market

PD-1 and PD-L1 inhibitors are highly growing immunotherapies that are being used in oncology therapy area. The pipeline of PD-1 and PD-L1 inhibitors is enriched with 47 drugs and there are approximately 245 active clinical studies. Currently, durvalumab from Astrazeneca and atezolizumab from Roche are among the most promising molecules in the pipeline, in terms of efficacy and safety. These molecules are in Phase III stage and expected to be launched in the coming years for the treatment of non-small cell lung cancer. There are many drugs in early stage of pipeline; thus, making PD1 and PDL1 inhibitors market very lucrative.

Among the different marketed PD-1 and PD-L1 inhibitor drugs, the largest revenue globally was generated from the sale of Opdivo in 2016. The global demand of Tecentriq is expected to witness high growth, primarily driven by the lack of approved competitor PD-L1 inhibitors drugs and high prevalence of urothelioma cancer.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/pd1-and-pdl1-inhibitors-market/report-sample

Some of the key players operating in the global market include Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Merck KGaA.

Innserspring Mattress Expected to be the Largest Segment in the Global Mattress Market by 2022

The global mattress market is expected to increase from $24,675.7 million in 2015 and reach $38,078.1 million by 2022, growing at a CAGR of 6.5%. The increasing population which is leading to increasing rate of home ownership is the key growth driver for the global mattress market. The demand for housing is mainly driven by migration of consumers from rural to urban areas. The high demand for new houses is observed mainly in the emerging regions including the Middle East and Asia-Pacific, where young consumers among the population are laying severe pressure on housing supply. The consumers’ preference towards customized mattresses is one of the major trends witnessed in the global market.

Explore Full Report at: https://www.psmarketresearch.com/market-analysis/mattress-market

The increasing population and growing numbers of nuclear families is increasing the demand for houses and consequently the market for mattress globally. The increasing migration of people from rural to urban areas, mainly in the Middle East and Asia-Pacific regions is also propelling the demand for mattresses. Owing to the surging property prices, home ownership is becoming one of the factors for social recognition in highly populated countries, such as India and China. The governments in several countries have also considered home ownership as an important policy goal, and consequently they incentivize it by creating mortgage interest payments.

Browse Related Research: https://www.psmarketresearch.com/industry-report/consumer-products

The major companies operating in the global mattress market include Tempur Sealy International Inc., Simmons Bedding Company LLC, Spring Air International Inc. LLC, Select Comfort Corporation, Kingsdown Inc., Reylon Beds, Southerland Bedding, and Corsicana Bedding Inc. 

Asia-Pacific Clinical Nutrition Market (largest market) Expected to grow at 6% CAGR during 2016 – 2022

The global clinical nutrition market was valued at $39,339.4 million in 2015, and it is expected to grow at a CAGR of 5.4% during 2016 - 2022. The factors driving the growth of the global market include increasing geriatric population, high birth rate and high number of premature birth, surge in the number of victims of malnutrition receiving treatment, surging incidence of lifestyle associated disease, and increasing incidence of cancer and central nervous system diseases. Malnutrition is a widespread problem, affecting the lives of millions of people globally. It is a condition that occurs due to deficiency of essential nutrients in the body. In 2010, around 40% of all hospital patients globally were malnourished. Clinical nutrition is the most efficient way to treat malnutrition and helps in avoiding associated costs. In Europe, around one-third of all hospital patients were malnourished in 2012. The increase in the number of victims of malnutrition globally, is expected to result in an increased usage of healthcare resource due to the longer stays in hospitals. As per an article of 2012, the malnutrition cost European government up to USD 237.0 billion a year; while the clinical nutrition accounted for about 2.5% of the cost involved with malnutrition.

Explore Full Report at: https://www.psmarketresearch.com/market-analysis/clinical-nutrition-market

The increasing incidence of cancer and central nervous system (CNS) diseases is driving the growth of the global enteral nutrition market. Enteral nutrition products are considered to be one of the best alternatives during the treatment of cancer and CNS diseases, to avoid nutrition deficiency in human body, for optimal functioning of various organs. Cancer can change the metabolism of nutrient uptake in patient’s body, therefore they require good nutrition. Cancer may lead to malnutrition and weight loss; therefore, patients are required continuous nutrient feeding. Enteral nutrition is one of the best solutions to the problem. According to the WHO, there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 globally. The organization also reported that 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions.

Ask for Report Sample: https://www.psmarketresearch.com/market-analysis/clinical-nutrition-market/report-sample

Moreover, with the increasing disposable income, increasing healthcare expenditure, and increasing awareness regarding nutrition is anticipated to fuel the growth of the Asia-Pacific clinical nutrition market. The different governments in the region are running awareness programs throughout these countries to encourage people for consuming nutritional diet. This would indirectly support the growth of the clinical nutrition market in the region.

Some of the major players operating in the global clinical nutrition market include Baxter International Inc., Abbott Laboratories, B. Braun Melsungen AG, Nestlé S.A., Groupe Danone, Mead Johnson Nutrition Company, Fresenius Kabi AG, and Perrigo Company Plc.

Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 by P&S Market Research

The study analyzed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, of which three products are in Phase III, three products in Phase II, one product in Phase I, and one product is in Discovery. The development of two BACE inhibitor candidates was found to be inactive, and five products were discontinued. BACE is a cleaving enzyme of aspartyl protease with beta-secretase activity. It acts as a precursor of beta-amyloid (Aβ) protein. In Alzheimer’s disease, the Aβ protein fragments get accumulated in plaques in the brain. BACE initiates Aβ production by cleaving amyloid precursor protein (APP) to generate APPβ and C99, which is critical for the subsequent cleavage of C99 by gamma-secretase to release Aβ1-40 and Aβ1-42. Inhibition of BACE enzyme disrupts the production of toxic Aβ and formed plaque and new soluble oligomers.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis

Insights on pipeline segments

As per the findings of the research, around 80% pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route and 7% by intravenous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.

Alzheimer’s disease drug development receives Fast Track designation

Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016. The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis/report-sample

Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Eisai & Co., Ltd., CoMentis, Inc., vTv Therapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Boehringer Ingelheim GmbH.

Start-Stop Technology Market Size, Share, Development and Demand Forecast to 2022

The global start stop technology market is projected to reach $7,058.0 million by 2022, growing at a CAGR of 18.8% during 2016 - 2022.

Global start-stop technology market worth $2,100.2 million in 2015

The study suggests that the global start-stop technology market is likely to grow from $2,100.2 million in 2015 to $7,058.0 million by 2022. Stringent emission control norms, increasing need for fuel efficient vehicles and increasing adoption of hybrid vehicles are that factors that are expected to drive the demand for start-stop technology over the forecast period.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/start-stop-technology-market

Insights on market segments

As per the findings of research, the enhanced starter was the largest contributor to the global start-stop technology market in 2015, in terms of volume and value; however, the integrated starter generator is expected to witness the highest growth, during the forecast period in terms of volume and value.

Enhanced starter and integrated starter generator-based start-stop systems are expected to dominate the market in future, and are expected to be used widely in passenger cars. Enhanced starter and integrated starter generator are more cost-effective and fuel efficient clean energy technologies as compared to direct starter and belt-driven alternator starter technologies.

Browse report Sample at: https://www.psmarketresearch.com/market-analysis/start-stop-technology-market/report-sample

Europe stands as the largest start-stop technology market

Geographically, Europe has been the largest market for start-stop technology, where the U.K. has been the largest contributor to the regional market. China is the major market in the Asia-Pacific region, while the U.S. remains the highest revenue generator in the North American Market. In the Rest of the World, Brazil was the largest market in the Latin American and the Middle-East and African countries.

Top six players account for major market share

The research states that the global start-stop technology market had a consolidated structure in 2015, where the top six competitors accounted for a major share of the market. Some of the key players in the global market include Robert Bosch GmbH, Continental AG, Denso Corporation, Delphi Automotive PLC, Johnson Controls, Inc, Hitachi, Ltd., Mitsubishi Electric Corporation, Valeo SA, and BorgWarner Inc.

Neurostimulation Device Market Analysis, Size, Development and Forecast to 2022

The global neurostimulation device market was valued at $5,656.1 million in 2015, and it is expected to grow at a CAGR of 12.9% during the period 2016 - 2022. The neurostimulation device market is growing, due to increasing geriatric population, increasing prevalence of chronic pain, and increasing incidents of neurological disorders. In addition, the awareness about mental diseases and their treatment is also increasing across the globe.

Explore The Potentials of Neurostimulation Devices Market at: https://www.psmarketresearch.com/market-analysis/neurostimulation-devices-market

Among the different types of neurostimulation devices, the implantable/interna neurostimulation segment is expected to witness the faster growth during the forecast period. Among the various applications, the pain management segment held the largest share in the global neurostimulation device market in 2015, and it is expected to witness the fastest growth during the forecast period.

The prevalence of chronic pain and neurological disorders is increasing globally, due to which the demand for better neurostimulation device is increasing. As a result, the research and development (R&D) investments in the development of novel and innovative neurostimulation devices are growing. The aim of increasing R&D investments in neurostimulation device is to offer better safety and efficacy to the patients. Moreover, the demand for minimally-invasive treatments is also growing in order to minimize pain and discomfort. As a result, the demand for new and effective medical technologies is expected to increase for the treatment of various neurological disorders.

Browse Related Research: https://www.psmarketresearch.com/industry-report/medical-devices

Some of the key companies operating in the global neurostimulation device market include Aleva Neurotherapeutics SA, St. Jude Medical Inc., Medtronic PLC, Boston Scientific Corporation, LivaNova PLC, Cochlear Ltd., Neuropace Inc., Neurosigma Inc., MED-EL GmbH, Synapse Biomedical Inc., Neuronetics Inc., NDI Medical LLC, EnteroMedics Inc., and ImThera Medical.

X-Ray Imaging Market Analysis, Size, Development and Demand Forecast to 2022

The global x-ray imaging market was valued at $8,897.3 million in 2015, and it is expected to grow at a CAGR of 4.9% during 2016-2022. Based on portability of x-ray imaging devices, the portable x-ray segment is expected to witness the faster growth, CAGR of 7.2%, during the forecast period.

The global x ray imaging market is growing at a significant rate, due to increasing healthcare expenditure, and growing geriatric population. The increasing prevalence of chronic diseases and improving healthcare infrastructure in developing countries are also driving the growth of the global x-ray imaging market.

Explore Report with Detailed TOC on “Global X-Ray Imaging Market” at: https://www.psmarketresearch.com/market-analysis/x-ray-imaging-market

X-rays are fragments of natural electromagnetic spectrum. Medical x-rays are used to generate images of tissues and structure inside the body. It is produced artificially by decelerating high-velocity electrons, with the help of X-ray tube. The x-rays when passed through the body are made to strike through a photographic film, which results in formation of the image of the area. The areas of the film exposed by x-ray are dark, whereas the unexposed areas are transparent. Now-a-days an X-ray image can also be stored in a digital form on a computer. The factors, such as stringent regulatory requirements for the approval of x-ray imaging devices and increasing risk of cancer, due to exposure to radiation are inhibiting the growth of the global market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/x-ray-imaging-market/report-sample

Geographically, North America dominated the global market of x-ray imaging in 2015; whereas the Asia-Pacific market is expected to witness the fastest growth at a CAGR of 5.7% during the forecast period.

Some of the key companies operating in the global x-ray imaging market include Siemens AG, Koninklijke Philips N.V., General Electric Company, Hitachi Ltd., Toshiba Corporation, Shimadzu Corporation, Carestream Health Inc., Hologic Inc., SAMSUNG, and Fujifilm Corporation.